May 29, 2024

Gastritis Treatment Market High Growth Opportunities, Emerging Trends, Industry Review, Forecast Till 2030

Gastritis refers to the inflammation of the stomach lining and can be caused due to infections like Helicobacter pylori (H. pylori) bacteria or use of nonsteroidal anti-inflammatory drugs (NSAIDs). Some common symptoms of gastritis include abdominal pain, nausea, vomiting and loss of appetite. Gastritis can lead to serious complications like gastric ulcers and increase risk of stomach cancer if left untreated. Currently available treatment options for gastritis include medications like antacids, antibiotics, proton pump inhibitors and H2 blockers. Antacids provide fast relief from symptoms by neutralizing stomach acid, while antibiotics are prescribed to treat H. pylori infections. Proton pump inhibitors (PPIs) and H2 blockers reduce acid production in the stomach for healing ulcers and relieving symptoms.

The global Gastritis Treatment Market is estimated to be valued at US$ 131.76 Bn in 2024 and is expected to exhibit a CAGR of 6.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Get more insights on this topic: https://www.coherentmarketinsights.com/market-insight/gastritis-treatment-market-148

Market key trends:

Increasing prevalence of gastric ulcers is a key trend fueling the growth of gastritis treatment market. Gastric ulcers developed in the lining of stomach as a result of gastritis are common worldwide. According to the Global Burden of Disease Study, around 4.4 million new cases of peptic ulcers were reported in the United States in 2017. Growing geriatric population is another factor positively impacting the market as people aged above 60 years are more prone to gastritis and gastric ulcers due to weakened immunity. Moreover, changing lifestyles including high stress levels, irregular eating habits and consumption of spicy and fatty foods have significantly increased the risk of gastritis, thereby driving the demand for effective treatment options. Introduction of new drug formulations with reduced dosing frequency and side effects is also contributing to market growth.

Porter’s Analysis

Threat of new entrants: The threat of new entrants in the gastritis treatment market is moderate. Established players have significant resources that allow them to invest in R&D and gain regulatory approvals, creating entry barriers.
Bargaining power of buyers: The bargaining power of buyers is high given the availability of generic drugs. Buyers can switch to lower cost generics easily.
Bargaining power of suppliers: The bargaining power of suppliers is moderate as innovation in gastritis treatment is driven by large pharmaceutical companies who have significant control over raw materials and IP.
Threat of new substitutes: The threat of substitutes is low as there are limited treatment options for gastritis currently.
Competitive rivalry: Competition in the market is high as the top players compete for market share through continuous innovation and new drug launches.

Key Takeaways

The global gastritis treatment market is expected to witness high growth over the forecast period.
Regional analysis: North America holds the largest share of the gastritis treatment market currently due to rising healthcare expenditure and the presence of key players in the region. The Asia Pacific region is expected to witness the highest growth rate owing to growing medical tourism, rapidly improving healthcare infrastructure, and rising focus of international players on emerging Asian countries.

Key players operating in the gastritis treatment market are Pfizer Inc., AstraZeneca plc, Johnson & Johnson, Novartis AG, Takeda Pharmaceutical Company Limited. Pfizer, AstraZeneca and Takeda are currently among the top three global players. Pfizer offers proton pump inhibitors like Nexium for gastritis treatment.

*Note:

  1. Source: Coherent Market Insights, Public sources, Desk research
  2. We have leveraged AI tools to mine information and compile it